ECM3 was not associated with any clinico-pathological variables (Table 1) and it was not found associated with worse prognosis in these cases, but a trend toward better prognosis was observed (Figure 3), suggesting that ECM3 cases could benefit from trastuzumab treatment.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}